A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine

Pierre Van Damme; Koen Van Herck

doi:10.1586/14760584.3.3.249

A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine

Expert Rev Vaccines. 2004 Jun;3(3):249-67. doi: 10.1586/14760584.3.3.249.

Authors

Pierre Van Damme¹, Koen Van Herck

Affiliation

¹ Unit of Epidemiology and Social Medicine, Centre for the Evaluation of Vaccination, WHO Collaborating Centre for the Prevention and Control of Viral Hepatitis, University of Antwerp, Campus 3 Eiken, Wilrijk, Belgium. pierre.vandamme@ua.ac.be

PMID: 15176942
DOI: 10.1586/14760584.3.3.249

Abstract

Hepatitis A and B are two of the most common vaccine-preventable liver diseases and continue to be a significant cause of morbidity and mortality worldwide, with their severity related to the individual's age upon initial infection. Twinrix (GlaxoSmithKline), a combined vaccine providing protection against both hepatitis A and B, has been available in more than 72 countries worldwide since 1997. This paper provides a critical review of clinical data on the efficacy, immunogenicity and tolerability of the combined vaccine, with particular focus on the clinical benefits of dual vaccination.

Publication types

Review

MeSH terms

Clinical Trials as Topic
Hepatitis A / immunology
Hepatitis A / prevention & control
Hepatitis A Vaccines / administration & dosage*
Hepatitis A Vaccines / adverse effects
Hepatitis A Vaccines / immunology*
Hepatitis Antibodies / blood
Hepatitis B / immunology
Hepatitis B / prevention & control
Hepatitis B Vaccines / administration & dosage*
Hepatitis B Vaccines / adverse effects
Hepatitis B Vaccines / immunology*
Humans
Immunization Schedule
Vaccines, Combined / administration & dosage
Vaccines, Combined / immunology

Substances

Hepatitis A Vaccines
Hepatitis Antibodies
Hepatitis B Vaccines
Vaccines, Combined
twinrix